Sanai Health Industry Group Company Limited provided group earnings guidance for the year ended December 31, 2023. For the period, the company expected that the Group will record a significant decrease in revenue and gross profit margin, which resulted in the substantial decrease in net profit attributable to the owner of the Company of not more than 40% as compared with that for the corresponding period of 2022. The significant decrease in revenue and gross profit margin was mainly attributable to the decrease in sales volume of self-manufactured pharmaceutical products and substantial increase in the general costs of traditional Chinese herb materials in the PRC during the Reporting Period.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.027 HKD | -3.57% | 0.00% | -57.81% |
1st Jan change | Capi. | |
---|---|---|
-57.81% | 13.71M | |
+37.78% | 723B | |
+31.40% | 598B | |
-3.51% | 364B | |
+19.94% | 331B | |
+5.14% | 288B | |
+16.47% | 244B | |
-4.62% | 208B | |
+10.14% | 210B | |
+9.32% | 169B |
- Stock Market
- Equities
- 1889 Stock
- News Sanai Health Industry Group Company Limited
- Sanai Health Industry Group Company Limited Provides Group Earnings Guidance for the Year Ended December 31, 2023